Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.52 |
| ▸ | MAOA | P21397 | 7/20 | 0.52 |
| ▸ | KDM1A | O60341 | 6/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21893525 | 0.89 | MAOB (0.43) | MAOBMAOAKDM1ACYP2C19CYP2B6 | |
| SCHEMBL14026071 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 | |
| SCHEMBL4606959 | 0.86 | SLC18A3 (0.54) | MAOBMAOAKDM1ACYP2C19CYP2B6 | |
| SCHEMBL17846315 | 0.86 | SLC18A3 (0.54) | MAOBMAOAKDM1ACYP2C19CYP2B6 | |
| SCHEMBL8746667 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 | |
| SCHEMBL1149307 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 | |
| SCHEMBL15178310 | 0.86 | SLC18A3 (0.54) | MAOBMAOAKDM1ACYP2C19CYP2B6 | |
| SCHEMBL3414993 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 | |
| SCHEMBL3693152 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 | |
| SCHEMBL407263 | 0.86 | SLC18A3 (0.59) | CYP1A2CYP2D6CYP2C9BLMSLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | claimed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2020-04-09 | — | — | US | disclosed |
| CN-101967146-B | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC | 2015-04-08 | — | — | CN | disclosed |
| EP-0866090-B1 | Improved PVC foam compositions | MORTON INT INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-5866625-A | DENSITY REDUCED BY THE USE OF AN ORGANOTIN HALIDE IN COMBINATION WITH A MERCAPTOCARBOXYLIC ACID ESTER OR A SULFIDE OF SUCH ESTER | MORTON INTERNATIONAL, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0866090-A1 | Improved PVC foam compositions | MORTON INTERNATIONAL, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5783613-A | ORGANOTIN COMPOUNDS AS ACTIVATOR FOR BLOWING AGENT | MORTON INTERNATIONAL, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| US-5710188-A | HEATING A MIXTURE OF POLYVINYL CHLORIDE, A BLOWING AGENT, AN ORGANOTIN HALIDE AND A STABILIZER TO FOAM POLYMER | MORTON INTERNATIONAL, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-RE30338-E | A DIORGANO-TIN SULFIDE AND A- OR B-MERCAPTO CARBOXY ESTER FOR PVC | ARGUS CHEMICAL CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | MAOB 4500/4885MAOA 4632/4885KDM1A 2228/4885 |
| US-20200109141-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | MAOB 4500/4885MAOA 4632/4885KDM1A 2228/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | MAOB 4667/4885MAOA 4710/4885KDM1A 1874/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | MAOB 4667/4885MAOA 4710/4885KDM1A 1874/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | MAOB 4667/4885MAOA 4710/4885KDM1A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.